Release of the 2024 National Survey on Drug Use and Health: Leveraging the Latest Substance Use and Mental Health Data to Make America Healthy Again
Impact on your practice
NSDUH data releases inform federal policy direction and funding priorities for behavioral health. Therapists should understand these epidemiological trends as they shape reimbursement, regulatory focus, and workforce demand.
Key facts
2024 National Survey on Drug Use and Health (NSDUH) data release from SAMHSA
Provides national epidemiological data on mental health, substance use, addiction, overdose, and suicide trends
Data informs federal policy priorities, funding allocations, and clinical practice guidelines
Therapy Companion analysis
The 2024 NSDUH data signals a bifurcated market opportunity and challenge for your practice. On one hand, nearly 50 million Americans (16.8% of the population) meet diagnostic criteria for a substance use disorder, yet only 19.3% received treatment in the past year—a massive treatment gap that represents potential revenue if your practice expands into SUD services or develops referral partnerships. However, only 11.3% of 18-to-25-year-olds with SUDs received treatment, suggesting that reimbursement barriers (prior authorization, insurance denials, low Medicaid rates) remain significant obstacles to closing this gap. For mental health specifically, the data is more encouraging: 52.1% of adults with any mental illness and 70.8% of those with serious mental illness received treatment, indicating mature demand and likely better insurance coverage. Adolescent mental health presents the highest clinical acuity—with 23.1% experiencing mild anxiety, 18.8% moderate-to-severe anxiety, and 15.4% experiencing major depressive episodes—but also the highest treatment rate (60.6% of adolescents with MDE received care). This means your practice's reimbursement from pediatric mental health cases may be more stable than SUD cases, but you should anticipate increasing volume and potential staffing strain. The data also reveal that 5.5% of adults (14.3 million) report serious suicidal ideation and 0.8% attempted suicide in the past year, which directly impacts your documentation, risk assessment, and liability exposure—expect heightened regulatory scrutiny and potential increases in malpractice insurance costs if your practice serves this population. Polysubstance use trends (cannabis, hallucinogens, opioids, benzodiazepines, and emerging substances like xylazine and nitazenes) mean your clinical assessment tools may be outdated; you'll need to update intake forms and screening protocols to reflect the toxicity and unpredictability of the current supply.
Background
The 2024 NSDUH represents the first comprehensive national substance use and mental health snapshot since 2020, with four years of comparable trend data (2021-2024) that will directly inform federal funding allocations, state Medicaid policy changes, and regulatory priorities under the Trump Administration's 'Making America Healthy Again' agenda. SAMHSA released this data unusually early in 2025 to drive policy and program direction, signaling that behavioral health will be a high-priority focus area for federal agencies, states, and insurers. The epidemiological picture has shifted: while some substance use metrics have improved (declines in past month tobacco and alcohol use, decreases in cocaine and prescription opioid misuse), concerning trends in cannabis, hallucinogens, and illicit drug use generally are accelerating, alongside persistent mental health crises in young adults (18-25 year-olds have the highest rates of anxiety, depression, and suicidal ideation across all age groups). The emergence of novel psychoactive substances (xylazine, medetomidine, illicit benzodiazepines) and the proliferation of fentanyl-adulterated street drugs have fundamentally altered the clinical presentation and treatment urgency of SUD cases. Concurrently, social media and technology-driven social stressors are linked to declining mental health in adolescents and young adults, creating a cohort that will drive treatment demand for the next 10-15 years. This data release signals that federal policy will likely prioritize funding for early intervention, adolescent mental health services, and integrated SUD-mental health treatment models, which may shift insurance coverage requirements and prior authorization criteria toward these areas.
What you should do
Audit your current mental health screening protocols and intake assessments immediately to ensure they capture GAD-7 and PHQ-9 validated measures and assess for suicidal ideation using evidence-based tools (Columbia-Suicide Severity Rating Scale or similar), as insurers and state regulators are increasingly requiring these standardized measures for adults and adolescents given the new NSDUH baseline on anxiety and suicide attempts.
Expand your substance use assessment procedures to screen specifically for polysubstance use patterns and emerging drugs (cannabis + opioids, benzodiazepines + fentanyl, xylazine co-use) during initial intake, and document clearly whether clients meet SUD diagnostic criteria under DSM-5, as this will become critical for justifying medical necessity and frequency of treatment to insurers facing heightened federal scrutiny on SUD treatment gaps.
If your practice does not currently serve adolescents (ages 12-17), develop a referral network or consider adding adolescent-focused clinicians, as the data show 18.8% have moderate-severe anxiety and 23.1% have mild anxiety, but treatment rates remain below 50% for anxiety disorders in this age group, indicating an underserved market segment with high insurance coverage (most adolescents with MDE receive treatment).
Review your Medicaid contracts and payer panels to identify which insurance plans offer coverage for integrated mental health and SUD treatment in a single episode, as federal policy will likely incentivize this model; begin documenting co-occurring conditions (e.g., major depressive episode + cannabis use disorder) to justify longer treatment episodes and higher frequency sessions.
Prepare for increased regulatory documentation requirements around suicide risk assessment and safety planning, particularly for young adults (18-25), given that 15.9% of this age group experienced major depressive episodes and 9.4% experienced serious mental illness in 2024; consider implementing standardized safety planning templates and documenting suicide risk stratification (ideation vs. plan vs. intent) at each session.
Notable excerpts
In 2024, approximately 1 in 4 Americans 12 years or older (73.6 million; 25.5%) reported illicit drug use in the past year... approximately 14,800 new users of nicotine vaping, 11,500 new users of alcohol, 7,900 new users of marijuana each day in 2024.
In 2024, nearly 50 million Americans, 16.8% of people 12 years or older, met diagnostic criteria for a substance use disorder in the past year... only 19.3% of people who needed substance use treatment actually received treatment.
Among adults 18 years or older, 5.5% (14.3 million) reported serious thoughts of suicide in the past year, 1.8% (4.6 million) made a suicide plan, and 0.8% (2.2 million) attempted suicide.
Among adolescents aged 12 to 17, 15.4% (3.8 million) had a past year major depressive episode and 11.3% (2.8 million) had a past year major depressive episode with severe impairment in 2024.
View full source text
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
One Student's Quick Thinking Shows Coordinated Action Through SAMHSA Program on Youth Mental Health Works
SAMHSA funding for school-based programs like Project AWARE generates referrals to therapists and expands youth access to mental health services. Therapists should understand these pipeline programs when engaging with schools.
On World AIDS Day, SAMHSA reaffirms commitment to Ending HIV Epidemic with support from partners
This signals federal funding and grant opportunities for therapists and agencies in high-burden HIV areas, particularly around integrated testing and treatment linkage. Therapists in targeted geographic areas should monitor MAI grant cycles.
New SAMHSA Guide Highlights HIV Prevention and Treatment for People with Substance Use and/or Mental Disorders
This SAMHSA clinical guidance can help therapists improve outcomes for high-risk populations with co-occurring conditions. It may also inform insurance companies' expectations for evidence-based treatment, potentially affecting prior authorization decisions.
SAMHSA Illuminates Paths to SUD Treatment
SAMHSA awareness campaigns increase demand for SUD treatment and recovery services, generating referrals to therapists. However, this item is campaign messaging rather than concrete policy change.